Mendus (IMMU) Corporate presentation summary

Addressing tumor recurrence in cancer

• Focus on preventing tumor recurrence, the leading cause of cancer-related deaths, with lead product vididencel targeting residual disease post first-line treatment in AML.

• Vididencel aims to improve relapse-free and overall survival in AML, with expanded development into CML and early-stage work in ovarian and other solid tumors.

Clinical efficacy and safety of vididencel

• Phase 2 proof-of-concept in high-risk AML shows durable clinical remissions, with majority of patients alive at 55 months median follow-up.

• Excellent safety profile observed, with adverse events limited to mild, local injection reactions.

• Immunological data confirm mode of action, with broad anti-leukemic immune responses across AML subtypes.

Clinical development and trial landscape

• ADVANCE II Phase 2a trial in MRD+ AML demonstrates 5-year overall survival estimate of 63%, significantly higher than historical standard of care.

• CADENCE Phase 2b trial combines vididencel with oral azacitidine for patients in CR1 post-chemotherapy; DIVA Phase 1b will study combination with venetoclax plus azacitidine.

• Ongoing and planned trials in CML (VITAL-CML, VITAL-TFR2) and ovarian cancer (ALISON) expand the pipeline.